- Home
- VRNS vs SUPN Comparison
VRNS vs SUPN Comparison
Compare VRNS & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRNS | SUPN |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.0B |
| IPO Year | 2013 | 2010 |
Fundamental Metrics
Financial Performance| Metric | VRNS | SUPN |
|---|---|---|
| Price | $30.65 | $49.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 5 |
| Target Price | $42.75 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 2.5M | 646.7K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $270,288,000.00 | ★ $392,755,000.00 |
| Revenue This Year | $18.87 | $22.70 |
| Revenue Next Year | $17.77 | $19.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 24.35 | N/A |
| 52 Week Low | $19.70 | $31.16 |
| 52 Week High | $63.90 | $59.68 |
Technical Indicators
Market Signals| Indicator | VRNS | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 72.70 | 46.57 |
| Support Level | $30.52 | $47.73 |
| Resistance Level | $34.07 | $52.36 |
| Average True Range (ATR) | 1.39 | 2.18 |
| MACD | 0.20 | -0.16 |
| Stochastic Oscillator | 97.55 | 34.97 |
Price Performance
Historical ComparisonAbout VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.